Longitudinal Changes in Relative Market Share Proportions of Biologic, and Targeted Synthetic, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) for Treatment of Rheumatoid Arthritis: Results from the Ontario Best Practices Research Initiative (OBRI)
Conferences